GPT and COVID-19: In 14–53% of COVID-19 patients, the disease was associated with hepatic dysfunction or liver damage, as indicated by elevated transaminases (AST, ALT) and cholestatic parameters (GGT, total bilirubin, ALP), and hepatic involvement was linked to a more severe outcome [7].